USF inventors have discovered 2-acetyl-1,3-cyclopentanedione (ACDP), which has the potential to prevent the development of, or reverse/diminish the pre-existing presence of these metabolic disorders. The technology is a novel, highly specific, potent, small molecular weight inhibitor of both atypical PKCs, PKC-zeta and PKC-lambda/iota. Effective treatment by a single agent for these abnormalities has the potential to solve what is perhaps the biggest health issue of the present era: the obesity/metabolic syndrome/type 2 diabetes pandemic that underlies many additional health complications. This technology is directly applicable to the health care and pharmaceutical industries that are involved in the prevention and the treatment of metabolic disorders.
ACPD Prevents Development of Glucose Intolerance in High-Fat-Fed (HFF) Mice